1.Halliday B, Gulati A, Ali A, Guha K, Newsome SJ, Arzanauskaite M, Vassiliou VS, Lota AS, Izgi C, Tayal U et al: Association Between Mid-Wall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients with Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation 2017, 135: 2106–2115.
2.Leyva F, Taylor RJ, Foley PWX, Umar F, Mulligan LJ, Patel K, Stegemann B, Haddad T, Smith REA, Prasad SK: Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology 2012, 60(17):1659–1667.
3.Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ: Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. Journal of the American College of Cardiology 2006, 48(10):1977–1985.
4.Masci PG, Doulaptsis C, Bertella E, Del Torto A, Symons R, Pontone G, Barison A, Droogné W, Andreini D, Lorenzoni V et al: Incremental Prognostic Value of Myocardial Fibrosis in Patients With Non–Ischemic Cardiomyopathy Without Congestive Heart Failure. Circulation: Heart Failure 2014, 7(3):448–456.
5.Saran R, Li Y, Robinson B, Abbott KC, Agodoa LYC, Ayanian J, Bragg-Gresham J, Balkrishnan R, Chen JLT, Cope E et al: US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases 2016, 67(3, Supplement 1):A7-A8.
6.Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP: Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease: The Role of Cardiovascular Magnetic Resonance. JACC: Cardiovascular Imaging 2014, 7(7):703–714.
7.Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006, 69(10):1839–1845.
8.Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse Intermyocardiocytic Fibrosis in Uraemic Patients. Nephrology Dialysis Transplantation 1990, 5(1):39–44.
9.Edwards NC, Moody WE, Yuan M, Hayer MK, Ferro CJ, Townend JN, Steeds RP: Diffuse Interstitial Fibrosis and Myocardial Dysfunction in Early Chronic Kidney Disease. American Journal of Cardiology, 115(9):1311–1317.
10.Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease: A Randomized Controlled Trial. Journal of the American College of Cardiology 2009, 54(6):505–512.
11.Levey AS, Coresh J, Greene T, et al.: USing standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of Internal Medicine 2006, 145(4):247–254.
12.Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA: Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015, 17(1):29.
13.Maceira AM, Prasad SK, Khan M, Pennell DJ: Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006, 8417–26
14.Schietinger BJ, Brammer GM, Wang H, Christopher JM, Kwon KW, Mangrum AJ, Mangrum JM, Kramer CM: Patterns of Late Gadolinium Enhancement in Chronic Hemodialysis Patients. JACC: Cardiovascular Imaging 2008, 1(4):450–456.
15.Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC: Evaluation of Techniques for the Quantification of Myocardial Scar of Differing Etiology Using Cardiac Magnetic Resonance. JACC: Cardiovascular Imaging 2011, 4(2):150–156.
16.Yi J-E, Park J, Lee H-J, Shin DG, Kim Y, Kim M, Kwon K, Pyun WB, Kim YJ, Joung B: Prognostic implications of late gadolinium enhancement at the right ventricular insertion point in patients with non-ischemic dilated cardiomyopathy: A multicenter retrospective cohort study. PLOS ONE 2018, 13(11):e0208100.
17.Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M: Late Gadolinium Enhancement on CMR Predicts Adverse Cardiovascular Outcomes in Non-ischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Circulation: Cardiovascular Imaging 2013, 7(2): 250–258.
18.van de Schoor FR, Aengevaeren VL, Hopman MTE, Oxborough DL, George KP, Thompson PD, Eijsvogels TMH: Myocardial Fibrosis in Athletes. Mayo Clinic Proceedings 2016, 91(11):1617–1631.
19.Zhu Y, Park E-A, Lee W, Kim H-K, Chu A, Chung JW, Park JH: Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction. European Radiology 2015, 25(4):1190–1200.
20.Swift AJ, Rajaram S, Capener D, Elliot C, Condliffe R, Wild JM, Kiely DG: LGE Patterns in Pulmonary Hypertension Do Not Impact Overall Mortality. JACC: Cardiovascular Imaging 2014, 7(12):1209–1217.
21.Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ: The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Journal of the American College of Cardiology 2004, 43(12):2260–2264.
22.Bogun F, Desjardins B, Good E, Gupta S, Crawford T, Oral H, Ebinger M, Pelosi F, Chugh A, Jongnarangsin K et al: Delayed-Enhanced Magnetic Resonance Imaging in Non-Ischemic Cardiomyopathy: Utility For Identifying the Ventricular Arrhythmia Substrate. Journal of the American College of Cardiology 2009, 53(13):1138–1145.
23.Dandamudi S SJ, Hodge DO, Glockner JF and Chen HH: The Prognostic Significance of Late-Gadolinium Enhancement Identified by Cardiac MRI in Association with Renal Function. Journal of Molecular Biology and Molecular<Imaging 2015, 2(2):1021.
24.aus dem Siepen F, Baumgärtner C, Müller-Henessen M, André F, Messroghli D, Ochs M, Riffel J, Giannitsis E, Katus HA, Friedrich MG et al: Variability of cardiovascular magnetic resonance (CMR) T1 mapping parameters in healthy volunteers during long-term follow-up. Open Heart 2018, 5(1):e000717.
25.Rutherford E, Talle MA, Mangion K, Bell E, Rauhalammi SM, Roditi G, McComb C, Radjenovic A, Welsh P, Woodward R et al: Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney International 2016, 90(4):845–852.
26.Graham-Brown MPM, March DS, Churchward DR, Stensel DJ, Singh A, Arnold R, Burton JO, McCann GP: Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Kidney International 2016, 90(4):835–844.
27.Graham-Brown M, S. Singh A, S. Gulsin G, Levelt E, A. Arnold J, J. Stensel D, Burton J, P. McCann G: Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance. BMC Cardiovascular disorders 2018, 18 (1): 145.
28.Price A, Ferro CJ, Hayer MK, Steeds RP, Edwards NC, Townend JN: Premature Coronary Artery Disease and Early Stage Chronic Kidney Disease. QJM: An International Journal of Medicine 2017, 111(10):683–686.